专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009105178A3 LACRIMAL IMPLANTS AND RELATED METHODS 审中-公开
标题翻译： LACRIMAL植入物及相关方法
公开(公告)号：WO2009105178A3
公开(公告)日：2010-06-03
申请号：PCT/US2009000963
申请日：2009-02-17
申请人： QLT PLUG DELIVERY INC , JAIN RACHNA , SHIMIZU ROBERT W
发明人： JAIN RACHNA , SHIMIZU ROBERT W
IPC分类号： A61F9/007
CPC分类号： A61F9/0017 , A61B17/12022 , A61F9/00772 , A61F9/00781 , A61F2210/0061 , A61K9/0051 , A61M29/02 , A61M31/00 , A61M31/002 , A61M2207/00 , A61M2210/0612
摘要： Lacrimal implants (300) providing secure retention within the lacrimal punctum of an eye are described. The lacrimal implants can comprise a implant body (302) configured for at least partial insertion through the lacrimal punctum and into a lacrimal canaliculus. The implant body can include a deformable retention structure (308) that can be configured to substantially encapsulate an expandable retention element. In some examples, the expandable retention element can include a fluid absorbing material, which can be exposed to fluid such as via a fluid permeable retainer or a fluid permeable aperture (320). As the fluid absorbing material retains fluid (i.e., upon acceptance of fluid into the retention structure), its size increases and its shape can change to urge one or more portions of the retention structure outward, such as against a wall of the lacrimal canaliculus, thereby securely retaining the lacrimal implant within the punctum.
摘要翻译：描述了在泪液泪点内提供牢固保留的泪液植入物（300）。泪液植入物可以包括植入物主体（302），其被构造成用于至少部分插入通过泪点并进入泪小管。植入物主体可以包括可变形的保持结构（308），其可被配置为基本上包封可扩张的保留元件。在一些示例中，可扩张保持元件可以包括流体吸收材料，其可以暴露于流体，例如经由流体可渗透保持器或流体可渗透孔（320）。当流体吸收材料保留流体（即，在将流体接受到保持结构中时），其尺寸增加并且其形状可以改变以将保留结构的一个或多个部分向外推动，例如抵靠泪小管的壁，从而将泪道植入物牢固地保持在泪点内。

2. 发明申请

WO2009105178A2 LACRIMAL IMPLANTS AND RELATED METHODS 审中-公开
标题翻译： LACRIMAL植入物及相关方法
公开(公告)号：WO2009105178A2
公开(公告)日：2009-08-27
申请号：PCT/US2009/000963
申请日：2009-02-17
申请人： QLT PLUG DELIVERY, INC. , JAIN, Rachna , SHIMIZU, Robert W.
发明人： JAIN, Rachna , SHIMIZU, Robert W.
IPC分类号： A61F9/007
CPC分类号： A61F9/0017 , A61B17/12022 , A61F9/00772 , A61F9/00781 , A61F2210/0061 , A61K9/0051 , A61M29/02 , A61M31/00 , A61M31/002 , A61M2207/00 , A61M2210/0612
摘要： Lacrimal implants and related methods providing secure retention within the lacrimal punctum of an eye are described. The lacrimal implants can comprise a implant body configured for at least partial insertion through the lacrimal punctum and into a lacrimal canaliculus. The implant body can include a deformable retention structure that can be configured to substantially encapsulate an expandable retention element. In some examples, the expandable retention element can include a fluid absorbing material, which can be exposed to fluid such as via a fluid permeable retainer or a fluid permeable aperture. As the fluid absorbing material retains fluid (i.e., upon acceptance of fluid into the retention structure), its size increases and its shape can change to urge one or more portions of the retention structure outward, such as against a wall of the lacrimal canaliculus, thereby securely retaining the lacrimal implant within the punctum.
摘要翻译：描述了在泪液泪点内提供牢固保留的泪液植入物和相关方法。泪液植入物可以包括植入体，其构造成用于至少部分插入通过泪点并进入泪小管。植入物主体可以包括可变形保持结构，其可被配置为基本上包封可扩张保留元件。在一些示例中，可扩张保留元件可以包括流体吸收材料，其可以暴露于流体，例如经由流体可渗透保持器或流体可渗透孔。当流体吸收材料保持流体（即，在将流体接受到保持结构中时），其尺寸增加并且其形状可以改变以将保持结构的一个或多个部分向外推动，例如抵靠泪小管的壁，从而将泪道植入物牢固地保持在泪点内。

3. 发明申请

WO2009035562A2 DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS 审中-公开
标题翻译：用于持续释放治疗药物的药物
公开(公告)号：WO2009035562A2
公开(公告)日：2009-03-19
申请号：PCT/US2008/010487
申请日：2008-09-05
申请人： QLT PLUG DELIVERY, INC , UTKHEDE, Deepank , SHIMIZU, Robert W. , JAIN, Rachna , BOYD, Stephen , GIFFORD, Hanson S. , DE JUAN JR., Eugene , REICH, Cary J.
发明人： UTKHEDE, Deepank , SHIMIZU, Robert W. , JAIN, Rachna , BOYD, Stephen , GIFFORD, Hanson S. , DE JUAN JR., Eugene , REICH, Cary J.
IPC分类号： A61K9/00 , A61M5/14 , A61F2/02 , A61F9/00
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F2230/0069 , A61F2250/0067 , A61K31/5575 , A61K47/34 , A61L27/54 , A61L2300/41 , A61L2300/602 , A61L2300/802 , Y02A50/395
摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
摘要翻译：可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。注射可以在低于环境温度下进行。将混合物固化以形成固体药物基质核心。治疗剂可以是在约室温下的液体，其形成液滴在基质材料中的分散体。固体药物核心的表面例如通过切割管而暴露，并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。在一些实施方案中，插入体抑制治疗剂的释放，例如具有对治疗剂基本上不可渗透的材料，使得治疗量通过暴露表面释放，从而避免将治疗剂释放到非靶组织。

4. 发明申请

WO2007115261A3 DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM 审中-公开
标题翻译：用于NASOLACRIMAL系统的药物递送方法，结构和组合物
公开(公告)号：WO2007115261A3
公开(公告)日：2009-01-22
申请号：PCT/US2007065792
申请日：2007-04-02
申请人： QLT PLUG DELIVERY INC , DE JUAN EUGENE JR , REICH CARY , BOYD STEPHEN , GIFFORD HANSON S , DEEM MARK
发明人： DE JUAN EUGENE JR , REICH CARY , BOYD STEPHEN , GIFFORD HANSON S , DEEM MARK
IPC分类号： A61F2/12 , A61F2/14
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/0026 , A61F9/00772 , A61F9/00781 , A61F2220/0008 , A61F2250/0067 , A61F2250/0087 , A61K9/00 , A61K9/0017 , A61K9/06 , A61K31/215 , A61K31/216 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/573 , A61K47/34 , A61L31/16
摘要： An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.
摘要翻译：用于插入到患者的泪点中的植入物包括主体。主体具有远端，近端和它们之间的轴线。身体的远端可通过泪点向远端插入到小管腔内。身体包含药剂基质药物核心内的治疗剂。试剂基质暴露于泪液能够在持续的时间内有效的治疗剂释放到泪液中。身体具有设置在药剂基质上的护套以抑制药剂远离近端的释放。身体还具有被配置为接合腔壁组织的外表面，以便当设置在其中时阻止排出。在具体实施方案中，试剂基质包含非生物可吸收聚合物，例如与该试剂的非均匀混合物的硅氧烷。

5. 发明申请

WO2011066479A1 LACRIMAL IMPLANTS INCLUDING SPLIT AND INSERTABLE DRUG CORE 审中-公开
标题翻译： LACRIMAL IMPLANTS包括分离和无毒的药物核心
公开(公告)号：WO2011066479A1
公开(公告)日：2011-06-03
申请号：PCT/US2010/058129
申请日：2010-11-26
申请人： QLT PLUG DELIVERY, INC. , ZARINS, Sascha, K. , SCOTT, David, J. , THOLFSEN, David
发明人： ZARINS, Sascha, K. , SCOTT, David, J. , THOLFSEN, David
IPC分类号： A61F9/00 , A61F9/007
CPC分类号： A61F9/00772 , Y10T29/49826
摘要： Lacrimal implants providing secure, wedgable retention within a lacrimal punctum and associated canaliculus of an eye are disclosed. The lacrimal implants (300) can comprise an implant body (302), including first (304) and second portions (306), extending from a proximal end of the first portion to a distal end of the second portion. The second portion includes a retention projection (312). The implant body can also include a cavity longitudinally extending from the proximal end of the first portion toward the second portion, wherein the cavity is shaped and sized to receive an insertable actuator, and wherein the retention projection is configured to bias outward or change orientation when the insertable actuator is seated within the cavity.
摘要翻译：公开了提供眼泪内的泪点和相关小管中牢固，可楔形保留的泪液植入物。泪液植入物（300）可以包括从第一部分的近端延伸到第二部分的远端的包括第一（304）和第二部分（306）的植入体（302）。第二部分包括保持突起（312）。植入物主体还可以包括从第一部分的近端朝向第二部分纵向延伸的空腔，其中空腔的形状和尺寸被设计成容纳可插入的致动器，并且其中保持突起构造成向外偏置或改变取向，可插入致动器位于腔内。

6. 发明申请

WO2010085696A3 SUSTAINED RELEASED DELIVERY OF ONE OR MORE AGENTS 审中-公开
标题翻译：持续发放一个或多个代理商
公开(公告)号：WO2010085696A3
公开(公告)日：2010-11-04
申请号：PCT/US2010021868
申请日：2010-01-22
申请人： QLT PLUG DELIVERY INC , BUTUNER ZUHAL , UTKHEDE DEEPANK , SIM SYLVIE , WISEMAN DAVID J
发明人： BUTUNER ZUHAL , UTKHEDE DEEPANK , SIM SYLVIE , WISEMAN DAVID J
IPC分类号： A61M37/00 , A61F9/00 , A61K9/00
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F9/00781 , A61K31/165 , A61K31/216 , A61K31/5575 , A61K45/06 , A61K47/24 , A61K47/34
摘要： The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti- glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye.
摘要翻译：本文描述的泪道植入物递送系统和方法提供用于治疗疾病的治疗剂的受控释放，包括用拉坦前列素或其他抗青光眼剂治疗青光眼，高眼压症或升高的眼内压。还提供了使用拉坦前列素或其他抗青光眼剂与渗透促进剂如苯扎氯铵和/或人造泪液联合治疗疾病，包括青光眼，眼高压或升高的眼内压。还提供了植入物，其含有与患者眼睛相邻的泪点中的药物核心，用于治疗药物如用于治疗青光眼的拉坦前列素的治疗剂，所述药物核心含有聚合物如交联的硅氧烷，治疗剂药剂和赋形剂，其中所述赋形剂可以增加药剂从药物核心释放的速率，或者可以增加核心中的药物负载，而不损失药芯在芯内的期望均匀性，或者可以改善药物的保留性药剂在眼睛或泪液中，或者可以增加药剂对眼睛的角膜穿透。

7. 发明申请

WO2010096822A2 LACRIMAL IMPLANTS AND RELATED METHODS 审中-公开
标题翻译： LACRIMAL植入物及相关方法
公开(公告)号：WO2010096822A2
公开(公告)日：2010-08-26
申请号：PCT/US2010/025089
申请日：2010-02-23
申请人： QLT PLUG DELIVERY, INC. , RAPACKI, Alan, R. , RUBINCHIK, Valery , KJELLBOTN, Charles, R.
发明人： RAPACKI, Alan, R. , RUBINCHIK, Valery , KJELLBOTN, Charles, R.
IPC分类号： A61F9/00 , A61M37/00 , A61F2/14 , A61L27/52 , A61L27/04
CPC分类号： A61F9/00772 , A61F2250/0003 , A61K9/0051
摘要： Lacrimal implants and related methods providing secure, wedgable retention within a lacrimal punctum and associated canaliculus of an eye are disclosed. The lacrimal implants can comprise an implant body configured for at least partial insertion through the lacrimal punctum and into the canaliculus. The implant body can include first and second portions, and can extend from a proximal end of the first portion defining a longitudinal proximal axis to a distal end of the second portion defining a longitudinal distal axis. The implant body can be configured such that, when implanted using an integral dilator, an angled intersection exists between the proximal and distal axes. In this way, at least a portion of the implant body can be biased against at least a portion of the lacrimal canaliculus located at or more distal to a canalicular curvature, thereby retaining an implanted position of the lacrimal implant using anatomical structures.
摘要翻译：公开了泪液植入物和相关方法，其提供眼泪内的泪点和相关小管内的牢固的可嵌入的保留。泪液植入物可以包括植入体，其构造成用于至少部分插入通过泪点并进入小管。植入体可以包括第一和第二部分，并且可以从限定纵向近端轴线的第一部分的近端延伸到限定纵向远侧轴线的第二部分的远端。植入物本体可以被配置为使得当使用整体式扩张器植入时，在近端和远端轴之间存在成角度的交叉。以这种方式，植入物主体的至少一部分可以抵靠位于或相对于小管曲率的远侧的泪小管的至少一部分偏置，从而使用解剖结构保留泪液植入物的植入位置。

8. 发明申请

WO2009134371A3 COMPOSITE LACRIMAL INSERT AND RELATED METHODS 审中-公开
标题翻译：复合材料插入和相关方法
公开(公告)号：WO2009134371A3
公开(公告)日：2010-08-12
申请号：PCT/US2009002611
申请日：2009-04-29
申请人： QLT PLUG DELIVERY INC , SIM SYLVIE , JAIN RACHNA , FARINAS KATHLEEN
发明人： SIM SYLVIE , JAIN RACHNA , FARINAS KATHLEEN
IPC分类号： A61K9/20
CPC分类号： A61L31/06 , A61F9/0008 , A61F9/0017 , A61K9/0051 , A61K47/34 , A61L31/145 , A61L31/16
摘要： Lacrimal implants, methods of making lacrimal implants, and methods of treating ocular, respiration or other diseases or disorders using lacrimal implants are disclosed.
摘要翻译：公开了泪液植入物，制造泪腺植入物的方法以及使用泪液植入物治疗眼睛，呼吸或其它疾病或障碍的方法。

9. 发明申请

WO2010085696A2 SUSTAINED RELEASED DELIVERY OF ONE OR MORE AGENTS 审中-公开
标题翻译：持续释放一个或多个代理商
公开(公告)号：WO2010085696A2
公开(公告)日：2010-07-29
申请号：PCT/US2010021868
申请日：2010-01-22
申请人： QLT PLUG DELIVERY INC , BUTUNER ZUHAL , UTKHEDE DEEPANK , SIM SYLVIE , WISEMAN DAVID J
发明人： BUTUNER ZUHAL , UTKHEDE DEEPANK , SIM SYLVIE , WISEMAN DAVID J
IPC分类号： A61M37/00 , A61F9/00 , A61K9/00
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F9/00781 , A61K31/165 , A61K31/216 , A61K31/5575 , A61K45/06 , A61K47/24 , A61K47/34
摘要： The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti- glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye.
摘要翻译：本文所述的泪管植入物递送系统和方法提供用于治疗疾病的治疗剂的受控释放，包括用拉坦前列素或其他抗青光眼剂治疗青光眼，高眼压或升高的眼内压。还提供了使用拉坦前列素或其他抗青光眼剂与渗透促进剂如苯扎氯铵和/或人工泪液联合治疗疾病，包括青光眼，高眼压或升高的眼内压。还提供了一种植入物，其含有药物核心，所述药物核心可嵌入邻近患者眼睛的泪点中，用于控制释放治疗剂，例如用于治疗青光眼的拉坦前列素，药物核心包含聚合物如交联硅酮，治疗剂药剂和赋形剂，其中赋形剂可以增加药剂从药心的释放速率，或者可以增加药心在药心中的负载量而不损失药心内药剂的期望的均匀性，或者可以改善眼药水或泪液中的药剂，或可以增加药剂对眼睛的角膜渗透。

10. 发明申请

WO2009035562A3 DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS 审中-公开
标题翻译：药物核心用于持续释放治疗药物
公开(公告)号：WO2009035562A3
公开(公告)日：2009-07-02
申请号：PCT/US2008010487
申请日：2008-09-05
申请人： QLT PLUG DELIVERY INC , UTKHEDE DEEPANK , SHIMIZU ROBERT W , JAIN RACHNA , BOYD STEPHEN , GIFFORD HANSON S , DE JUAN JR EUGENE , REICH CARY J
发明人： UTKHEDE DEEPANK , SHIMIZU ROBERT W , JAIN RACHNA , BOYD STEPHEN , GIFFORD HANSON S , DE JUAN JR EUGENE , REICH CARY J
IPC分类号： A61K9/00 , A61F2/02 , A61F9/00 , A61M5/14
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F2230/0069 , A61F2250/0067 , A61K31/5575 , A61K47/34 , A61L27/54 , A61L2300/41 , A61L2300/602 , A61L2300/802
摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
摘要翻译：可以通过将包含治疗剂和基质前体的液体混合物注射到鞘体中来制造固体药心插入物。注射可以在低于环境温度下进行。混合物固化形成固体药物基质核心。治疗剂在约室温下可以是液体，其在基质材料中形成液滴分散体。例如通过切割管暴露固体药物核心的表面，并且当植入患者体内时，固体药物核心的暴露表面释放治疗量的治疗剂。在一些实施方案中，插入体抑制治疗剂的释放，例如用治疗剂基本上不可渗透的材料，使得治疗量通过暴露的表面释放，由此避免治疗剂释放到非靶组织。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式